Navigation Links
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
Date:6/30/2008

n drugs, concerning the risk of liver toxicity and the possibility of heart attacks.

Sangamo's ZFN technology represents a means of potentially circumventing these limitations or risks by specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs. This results in permanent modification of the CCR5 protein such that HIV cannot enter and infect the cells. This approach could potentially enable the generation of a reservoir of protected CD4 T-cells that are available to fight the opportunistic infections that are characteristic of AIDS as well as HIV itself. Sangamo expects to initiate a clinical trial to evaluate this approach by the end of the year.

Data Reported in the Nature Biotechnology Paper

The reported results demonstrate that a one-time exposure to CCR5-specific ZFNs resulted in the generation of an HIV-resistant population of human primary T-cells by the permanent genetic modification of the CCR5 gene. These ZFN-modified CD4 T-cells expanded stably in HIV-infected cultures for several weeks and appeared to behave identically to untreated T-cells except that they were resistant to infection by HIV. ZFN treated primary CD4 T-cells and transformed CD4 cell lines resisted infection with R5-tropic HIV (virus that uses the CCR5 co-receptor to enter cells), resulting in enrichment of ZFN- generated CCR5-disrupted cells in the population upon long-term exposure to virus (>50 days). Importantly, in the presence of HIV, ZFN-modified CD4 T- cells also preferentially expanded in a mouse model. The modified cells were infused into mice that lack a normal immune system and thus do not reject human cells. After 33 days, the mice were sacrificed and analyzed for the presence of ZFN-modified cells. Researchers determined that ZFN-modified cells engrafted normally in the mouse and that the proportion of modified cells present at the end of the experiment was greater than two to three fold hi
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
2. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
6. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
7. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
10. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 Henry Schein ... provider of health care products and services to ... reminded its customers that the Henry Schein Disaster ... veterinarians who experience operational, logistical or financial issues ... the South Central region of the U.S. The ...
(Date:5/28/2015)... This report analyzes the worldwide markets for Intraocular ... Segments: Standard Intraocular Lenses, and Premium Intraocular Lenses. The report ... , Japan , Europe ... America , and Rest of World. Annual estimates and ... a seven-year historic analysis is provided for these markets. Market ...
(Date:5/28/2015)... 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... A. Martell , to the position of Executive Chairman. ... KaloBios Board of Directors. In this new role, he ... to refine and execute on the strategic plan to ... therapeutics for orphan oncology indications with high unmet medical ...
Breaking Medicine Technology:Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5
... years after the identification of,the gene responsible for ... a team of Spanish and French researchers (Carlos,Lopez-Otin ... Nicolas Levy and coll. -,Inserm/AP-HM, Marseille, France) have ... This treatment, combining two existing,pharmacological molecules, should slow ...
... Evaluating the, Anti-Tumor Activity of Bavituximab in Combination with Carboplatin ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that patient screening,and ... safety,and efficacy of bavituximab in combination with chemotherapy in patients,with non-small cell ...
Cached Medicine Technology:Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... giving patients a long-lasting impression on what modern dentistry ... VisitandCare.com is on a mission to revolutionize the perception ... with a high-class Wellness & Spa. , The ... world’s most successful medical tourism agencies and ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 Healthpointe ... brain injuries with the help of their licensed clinical ... traumatic brain injuries can lead to an extensive array ... these effects can arise at any time after a ... be caused by any bump or jolt to the ...
(Date:5/29/2015)... Arlington, VA (PRWEB) May 29, 2015 ... into a new U.S. headquarters and a larger team, ... market and increase CloverETL's market share in the U.S. ... of the Javlin Group, achieved significant growth in 2014 ... sales of Javlin’s premier data integration platform, CloverETL. To ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by the American Society ... May 14-19th. This global event sets a gold standard ... dedicating itself exclusively to cosmetic medicine. Dr. Paul Vitenas ... to attend this year’s meeting. , Among the classes and ... the honor of sitting at the presenter’s table during a ...
(Date:5/29/2015)... Healthpointe is excited to announce that ... at their clinics in Orange County. The Supartz Therapy ... in diminishing pain for patients with osteoarthritis, and will ... Dr. Neil Katz of Healthpointe. Supartz is an injection ... as hyaluronic acid) a natural substance found in joint ...
Breaking Medicine News(10 mins):Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:Healthpointe’s Los Angeles County Clinics Are Now Offering Treatment for Mild Traumatic Brain Injuries 2Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today ... dividend of $0.05 per share, payable on June ... 2008., Perrigo Company is a leading global ... and prescription,pharmaceuticals, nutritional products, active pharmaceutical ingredients,(API) and ...
... LAVAL, QC, May 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... its first quarter,fiscal 2008 results conference call and Annual ... On Thursday, May 8 at 8:30 a.m. (ET) ... quarter 2008 financial results. Labopharm will,report its first quarter ...
... Proven Efficacy in all Four ... Chambers of the Heart, Stereotaxis to Introduce Major New Software Platform for ... ... (Nasdaq:,STXS), announced today that approximately 15,000 procedures have been,performed using Stereotaxis, Niobe(R) Magnetic Navigation ...
... 1 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... operating room, will host a conference call and live,webcast ... to discuss the financial,results for the first quarter ended ... by telephone, dial 416-644-3422 or,1-800-731-5319. Please connect approximately ten ...
... published in the May 2008 edition of Otolaryngology ... several areas of hearing health, including research that indicates ... having cochlear implants placed in both ears, rather than ... are being released in conjunction with Better Hearing and ...
... Declines in Ozone and Particle Pollution Have,Stalled, ... its annual report card on air pollution today, ... short-term particle,pollution, year-round particle pollution and ozone pollution. ... Pittsburgh, Pennsylvania, tops one of,the most polluted lists ...
Cached Medicine News:Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 2Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 3Health News:Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases 4Health News:Novadaq to hold first quarter 2008 results conference call and webcast 2Health News:Novadaq to hold first quarter 2008 results conference call and webcast 3Health News:New research on hearing health underscores the importance of better hearing and speech month 2Health News:American Lung Association Issues State of the Air Report: First City Outside California (Pittsburgh) Tops One of the Most-Polluted Lists 2Health News:American Lung Association Issues State of the Air Report: First City Outside California (Pittsburgh) Tops One of the Most-Polluted Lists 3Health News:American Lung Association Issues State of the Air Report: First City Outside California (Pittsburgh) Tops One of the Most-Polluted Lists 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: